#ACR Best 2024 - Day 4

Jack Cush, MD

Nov 20, 2024 6:56 am

Although the last day of ACR Convergence 2024 was but a half day - it was chock full of gems, many coming from the late breaking abstracts presented today. As chosen by the RheumNow faculty, here are some highlight presentations you need to know about.

All-caps abstract text throw-down by Michelle Petri re:fractures in SLE 😆

I keep saying this; our obsesssion with vitamin d is not commensurate w/reality

It's. The. Prednisone. #ACR24 @RheumNow Abstr#2679 #ACRBest pic.twitter.com/13luByNvYT
— Mike Putman (@EBRheum) November 19, 2024

Lacaille et al. Long term harms of previous steroids in RA. CV/infection mortality increase 7% every year/use. Takes 3.5 and 10 years to return to normal after 1 and 2 years use. Never returns to normal if >2 years use @RheumNow #ACR24 Abstr#2673 #ACRbest https://t.co/qcp5mCHmeB pic.twitter.com/keXw5Qg2ld
— Richard Conway (@RichardPAConway) November 19, 2024

Bolhuis et al. PMR MODE study. MTX 25mg/week in recently diagnosed PMR. 52 weeks. 56 patients. Nada, zip, no effect. GC free remission 67% vs 68%. No difference in any secondary outcome. @RheumNow #ACR24 Abstr#1697 #ACRbest https://t.co/Mb909u1zFT pic.twitter.com/dShyBF4WST
— Richard Conway (@RichardPAConway) November 17, 2024

PHOENYCS GO, RCT of dapirplizumab, novel CD40Li in SLE

Met primary endpoint (NNT~6 for BICLA) & numerical improvements in many other endpts

1 MI & 1 death from infection over 213 pts

Encouraging for sure! Second phase 3 being launched #ACR24 @RheumNow Abstr#L16 #ACRbest pic.twitter.com/QwDMKjhFvb
— Mike Putman (@EBRheum) November 19, 2024

Dumoulin et al. 4 year results of TREAT EARLIER trial of 1 year MTX in CSA. In high risk ACPA- group, reduced risk of RA development, 8.6% vs 29%, HR 0.27. No difference at 4 years in ACPA+ or low risk ACPA- @RheumNow #ACR24 Abstr#2672 #ACRbest https://t.co/S2yJm196UV pic.twitter.com/bJ9JySteUs
— Richard Conway (@RichardPAConway) November 19, 2024

Another + #SLE #RCT - large N#Dapirolizumab = Peg CD40L + SoC
Vs #Placebo + SoC

Rapid improvemt
steroid sparing

So what to use in Pts if +Ph3
👇
TYK2 Deucravacitinib
JAKi Upadacitinib
Dapirolizumab
CAR 🚗 Rx
Anifrolimumab
Benlysta
ETC!#ACRBest L16 @RheumNow #ACR24 https://t.co/wTFucF7BYO
— Janet Pope (@Janetbirdope) November 19, 2024